{"id":4023,"date":"2019-01-31T12:53:19","date_gmt":"2019-01-31T07:23:19","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=4023"},"modified":"2021-07-24T12:57:11","modified_gmt":"2021-07-24T07:27:11","slug":"the-business-cocktail-54","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-54","title":{"rendered":"Voyager clears Neurocrine deal; Anthem speeds up launch; Lilly rushed its deal"},"content":{"rendered":"\n<p class=\"has-background has-pale-cyan-blue-background-color\"><strong>Voyager clears Neurocrine agreement for Parkinson&#8217;s\ngene therapy<\/strong><\/p>\n\n\n\n<p><strong>Voyager Therapeutics <\/strong>is signing a <strong>collaboration <\/strong>agreement with <strong>Neurocrine Biosciences<\/strong> that will remunerate the <strong>Cambridge, Massachusetts<\/strong>-based biotech <strong>USD 165 million<\/strong> upfront. In return, <a href=\"https:\/\/www.delveinsight.com\/report-store\/neuroendocrine-carcinoma-market\">Neurocrine <\/a>benefits certain rights to four gene therapy programs, including one in <a href=\"https:\/\/www.delveinsight.com\/report-store\/parkinsons-disease-market-size-analysis-treatment\">Parkinson&#8217;s disease<\/a> in an ongoing <strong>Phase 2 study<\/strong>. Voyager has previously collaborated with <strong>AbbVie and Sanofi Genzyme<\/strong>. Voyager, which will receive <strong>USD 1.7 billion<\/strong> in milestone payments from Neurocrine. &nbsp;<\/p>\n\n\n\n<p class=\"has-background has-pale-cyan-blue-background-color\"><strong>Anthem speeds up launch of PBM IngenioRx<\/strong><\/p>\n\n\n\n<p><strong>Anthem <\/strong>is accelerating the debut of its own pharmacy benefit <strong>IngenioRx<\/strong>. The fourth quarter earnings of the <strong>Blue Cross Blue Shield<\/strong> payer per share of <strong>USD 2.44<\/strong> beat expectations of analysts and stock price of Anthem shot up nearly 10%.&nbsp; Anthem had the modest revenue growth for both the fourth quarter and year-end. But net income fell to USD 424 million during the fourth quarter from USD 1.2 billion.<\/p>\n\n\n\n<p class=\"has-background has-pale-cyan-blue-background-color\"><strong>Lilly rushed its Loxo agreement to have a big\nreveal at J.P. Morgan<\/strong><\/p>\n\n\n\n<p><strong>Eli Lilly<\/strong> goes for accelerated acquisition of <strong>Loxo Oncology.<\/strong> It is done so that it could announce the agreement at <strong>J.P. Morgan Healthcare Conference<\/strong>. The agreement has remunerating <strong>USD 235 <\/strong>per Loxo share for a total valuation of USD 8 billion. Lilly representatives intended to swiftly finish due diligence and execute a transaction. Lilly was the only company to put up a bid for Loxo, which at the time was having trouble locking down a licensing agreement for its most advanced candidate, <strong>LOXO-292<\/strong>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Voyager clears Neurocrine agreement for Parkinson&#8217;s gene therapy Voyager Therapeutics is signing a collaboration agreement with Neurocrine Biosciences that will remunerate the Cambridge, Massachusetts-based biotech USD 165 million upfront. In return, Neurocrine benefits certain rights to four gene therapy programs, including one in Parkinson&#8217;s disease in an ongoing Phase 2 study. Voyager has previously collaborated [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4024,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[56,2507,2509,228,2508,2511,2396,2505,2506,2504],"industry":[17225],"therapeutic_areas":[17245,17228],"class_list":["post-4023","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-abbvie","tag-anthem","tag-blue-cross-blue-shield","tag-eli-lilly","tag-ingeniorx","tag-j-p-morgan-healthcare-conference","tag-loxo-oncology","tag-neurocrine-biosciences","tag-sanofi-genzyme","tag-voyager-therapeutics","industry-pharmaceutical","therapeutic_areas-neurology","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Voyager clears Neurocrine deal; Anthem speeds up launch; Lilly&#039;s deal<\/title>\n<meta name=\"description\" content=\"Voyager Therapeutics is signing a collaboration agreement with Neurocrine Biosciences that will remunerate the Cambridge, Massachusetts-based biotech....\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-54\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Voyager clears Neurocrine deal; Anthem speeds up launch; Lilly&#039;s deal\" \/>\n<meta property=\"og:description\" content=\"Voyager Therapeutics is signing a collaboration agreement with Neurocrine Biosciences that will remunerate the Cambridge, Massachusetts-based biotech....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-54\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-01-31T07:23:19+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/01\/04103828\/Opioid-Lawsuits-1068x587-1068x587.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1068\" \/>\n\t<meta property=\"og:image:height\" content=\"587\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Voyager clears Neurocrine deal; Anthem speeds up launch; Lilly's deal","description":"Voyager Therapeutics is signing a collaboration agreement with Neurocrine Biosciences that will remunerate the Cambridge, Massachusetts-based biotech....","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-54","og_locale":"en_US","og_type":"article","og_title":"Voyager clears Neurocrine deal; Anthem speeds up launch; Lilly's deal","og_description":"Voyager Therapeutics is signing a collaboration agreement with Neurocrine Biosciences that will remunerate the Cambridge, Massachusetts-based biotech....","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-54","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-01-31T07:23:19+00:00","article_modified_time":"2021-07-24T07:27:11+00:00","og_image":[{"width":1068,"height":587,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/01\/04103828\/Opioid-Lawsuits-1068x587-1068x587.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-54","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-54","name":"Voyager clears Neurocrine deal; Anthem speeds up launch; Lilly's deal","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-54#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-54#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/01\/04103828\/Opioid-Lawsuits-1068x587-1068x587.jpg","datePublished":"2019-01-31T07:23:19+00:00","dateModified":"2021-07-24T07:27:11+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Voyager Therapeutics is signing a collaboration agreement with Neurocrine Biosciences that will remunerate the Cambridge, Massachusetts-based biotech....","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-54"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-54#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/01\/04103828\/Opioid-Lawsuits-1068x587-1068x587.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/01\/04103828\/Opioid-Lawsuits-1068x587-1068x587.jpg","width":1068,"height":587,"caption":"parkinson's"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/01\/04103828\/Opioid-Lawsuits-1068x587-1068x587-300x165.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AbbVie<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Anthem<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Blue Cross Blue Shield<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Eli Lilly<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">IngenioRx<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">J.P. Morgan Healthcare Conference<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Loxo Oncology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Neurocrine Biosciences<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sanofi Genzyme<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Voyager Therapeutics<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AbbVie<\/span>","<span class=\"advgb-post-tax-term\">Anthem<\/span>","<span class=\"advgb-post-tax-term\">Blue Cross Blue Shield<\/span>","<span class=\"advgb-post-tax-term\">Eli Lilly<\/span>","<span class=\"advgb-post-tax-term\">IngenioRx<\/span>","<span class=\"advgb-post-tax-term\">J.P. Morgan Healthcare Conference<\/span>","<span class=\"advgb-post-tax-term\">Loxo Oncology<\/span>","<span class=\"advgb-post-tax-term\">Neurocrine Biosciences<\/span>","<span class=\"advgb-post-tax-term\">Sanofi Genzyme<\/span>","<span class=\"advgb-post-tax-term\">Voyager Therapeutics<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jan 31, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jan 31, 2019 12:53 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4023","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=4023"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4023\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/4024"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=4023"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=4023"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=4023"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=4023"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=4023"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}